Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Public Citizen petition: FDA denies consumer group's Nov. 3 petition requesting the agency halt review of Inamed's silicone gel-filled breast implants "until an amendment to the PMA is submitted responding to deficiencies" in clinical trial data (1"The Gray Sheet" Nov. 10, 2003, p. 19). The Dec. 4 letter informs the group that, following expedited review of the petition, FDA has concluded the 9-6 advisory panel vote and recommendation, along with further agency review, are sufficient for a premarket approval determination. "FDA is now completing its review of the PMA and the advisory committee report and recommendation to determine whether the PMA contains adequate data to demonstrate reasonable safety and effectiveness of Inamed's silicone gel-filled breast implants," the letter explains...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel